Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Up 107.2% in September

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 31,500 shares, an increase of 107.2% from the September 15th total of 15,200 shares. Approximately 2.3% of the company’s stock are sold short. Based on an average daily volume of 45,200 shares, the short-interest ratio is currently 0.7 days.

Institutional Trading of Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned 7.97% of Avenue Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 17.34% of the stock is currently owned by institutional investors.

Avenue Therapeutics Stock Performance

Avenue Therapeutics stock opened at $2.02 on Friday. Avenue Therapeutics has a fifty-two week low of $1.90 and a fifty-two week high of $47.25. The firm’s 50-day simple moving average is $2.55 and its 200 day simple moving average is $4.42. The stock has a market cap of $1.90 million, a PE ratio of -0.26 and a beta of -0.17.

Avenue Therapeutics (NASDAQ:ATXI) last released its earnings results on Friday, August 9th. The company reported ($6.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($5.38).

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.